The Richmond company (Nasdaq: BIOA) will get a fraction of the money upfront from Novartis (NYSE: NVS) — up to $20 million, ...
FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review ...
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Tuesday after initially jumping after the company ...
Pending FDA clearance of the IND application, Neurizon said it anticipated Massachusetts General Hospital filing a protocol ...
(ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce the filing of an Investigational New Drug ...
Stocktwits on MSN13h
Tonix Pharma Stock’s Retail Chatter Explodes After FDA Nod For New Drug ApplicationTonix Pharmaceuticals was the most active symbol on Stocktwits before the bell on Wednesday as shares of the clinical-stage ...
Even though AI-designed drugs aren’t yet a household term for FDA-approved, commercially available therapies, they are a ...
KalVista has an estimated pro forma cash balance of $292.2 million, which is expected to fund its operations into the 2H of ...
Stockhead on MSN19m
In big news week Neurizon secures key orphan status for motor neurone drug in EuropeEuropean Medicines Agency grants orphan drug designation for Neurizon’s lead drug candidate NUZ-001 to treat Amyotrophic ...
Limited announces that the U.S. Food and Drug Administration, FDA, has approved its suitability petition for a new animal drug ...
LONDON - A new class of weight loss drugs developed by Novo Nordisk and Eli Lilly “opens the possibility of an end to the ...
clinicaltrialsarena on MSN5d
FDA clears SpliceBio’s IND application to begin Stargardt disease therapy trialThe US FDA has granted clearance to SpliceBio’s IND application to begin the trial of SB-007, designed for Stargardt disease treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback